Seres Therapeutics, Inc. (MCRB)
After hours:
- Business Wire
Seres Therapeutics to Present at World Anti-Microbial Resistance Congress
CAMBRIDGE, Mass., September 08, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Matthew Henn, Ph.D., Chief Scientific Officer at Seres, will be presenting at the World Anti-Microbial Resistance Congress being held on September 7-8, 2022 in National Harbor, Maryland. Dr. Henn will present at 12:00 p.m. ET today a presentation entitled: "Microbiome Therapeutics to Potentially Transform the Management of Antimicrobial Resistant Infectio
- Business Wire
Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection
CAMBRIDGE, Mass., September 07, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for SER-109 for the prevention of recurrent C. difficile infection (rCDI). SER-109 is an entirely new treatment modality that shows promise to improve the current standard of care for rCDI.
- Simply Wall St.
Calculating The Intrinsic Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)
In this article we are going to estimate the intrinsic value of Seres Therapeutics, Inc. ( NASDAQ:MCRB ) by taking the...
